insights_auto
Pse është rritur AXGN 2,61%?
Zhytu më thellëchevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
50,02Â US$
arrow_upward
+2,61%(+1,27) 1D
50,00Â US$
arrow_downward
-0,04% (-0,020)bedtimeJashtë orarit
Mbyllur: 6 nĂ«n, 4:00:01 m.d., GMT-5 · USD
search
TĂ« gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për AXGN...
Hap
48,55Â US$
I lartë
50,29Â US$
I ulët
48,14Â US$
Kapitalizimi i tregut
2,99Â mld
VĂ«llimi mesatar
1,79Â mln
VĂ«llimi
1,67Â mln
Maksimumi 52-javor
52,91Â US$
Minimumi 52-javor
23,00Â US$
Fitimet për aksion
-0,68Â US$
Beta
1,21
Aksionet në qarkullim
59,73Â mln
Numri i punonjësve
622
Hap
48,55Â US$
I lartë
50,29Â US$
I ulët
48,14Â US$
Kapitalizimi i tregut
2,99Â mld
VĂ«llimi mesatar
1,79Â mln
VĂ«llimi
1,67Â mln
Maksimumi 52-javor
52,91Â US$
Minimumi 52-javor
23,00Â US$
Fitimet për aksion
-0,68Â US$
Beta
1,21
Aksionet në qarkullim
59,73Â mln
Numri i punonjësve
622
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Yahoo! Finance Canada
·
15 orë më parë
Axogen, Inc. (AXGN) Seasonal Returns Chart - Yahoo Finance
Profili
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Rreth AxoGen, Inc Common Stock
Drejtori ekzekutiv-
Punonjësit622
Themeluar më2002
SeliaAlachua, Florida, Shtetet e Bashkuara të Amerikës
SektoriHealth Care
IndustriaMedical device
Uebsajtiaxogeninc.com